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Modified vaccinia Ankara (MVA) is a safe and promising viral vaccine vector that is currently
investigated in several clinical and pre-clinical trials. In contrast to inactivated or sub-unit
vaccines, MVA is able to induce strong humoral as well as cellular immune responses.
In order to further improve its CD8 T cell inducing capacity, we genetically adjuvanted
MVA with the coding sequence of murine CD40L, a member of the tumor necrosis fac-
tor superfamily. Immunization of mice with this new vector led to strongly enhanced
primary and memory CD8 T cell responses. Concordant with the enhanced CD8 T cell
response, we could detect stronger activation of dendritic cells and higher systemic levels
of innate cytokines (including IL-12p70) early after immunization. Interestingly, acquisition
of memory characteristics (i.e., IL-7R expression) was accelerated after immunization with
MVA-CD40L in comparison to non-adjuvanted MVA. Furthermore, the generated cytotoxic
T-lymphocytes (CTLs) also showed improved functionality as demonstrated by intracellular
cytokine staining and in vivo killing activity. Importantly, the superior CTL response after a
single MVA-CD40L immunization was able to protect B cell deficient mice against a fatal
infection with ectromelia virus.Taken together, we show that genetic adjuvantation of MVA
can change strength, quality, and functionality of innate and adaptive immune responses.
These data should facilitate a rational vaccine design with a focus on rapid induction of
large numbers of CD8 T cells able to protect against specific diseases.
Keywords: vaccination, viral vaccines, CD8T cells,T cell memory, co-stimulation, modified vaccinia Ankara, CD40L,
ectromelia virus
INTRODUCTION
Decades of successful vaccine development led to a drastic reduc-
tion in child mortality and debilitating illness resulting from
infectious disease. Despite this impressive success, probably best
exemplified by the eradication of smallpox, an estimated 5.6 mil-
lion deaths annually can be accounted solely to the three most
devastating diseases: malaria, tuberculosis, and HIV/AIDS (1).
Other infectious diseases, such as Ebola and Marburg hemorrhagic
fever, are quite rare but accompanied by high fatality rates. More-
over, the corresponding viruses might be used as bioterrorism
agents. The common element linking these very diverse diseases is
the requirement for strong T cell responses as part of the adaptive
immune response to protect the host from infection. Because it
is generally accepted that an ideal vaccine should induce both, T
cells and antibodies, modern vaccinology is faced with the chal-
lenge to create a safe vaccine able to activate efficiently both arms
of the adaptive immune system. Among the many possible vaccine
modalities, live vector viruses seem best to fulfill this requirement
(2). While some live virus vaccines, such as vaccinia virus (VV)
and yellow fever virus are effective but have unfavorable safety
profiles, others, such as adenovirus (AdV), face problems due to
pre-existing immunity [reviewed in (3)]. A safe live vector vaccine
largely unaffected by pre-existing immunity (4–6) is modified
vaccinia virus Ankara (MVA), originally created by Anton Mayr
and further developed into a third-generation smallpox vaccine
(MVA-BN®, IMVAMUNE®) [reviewed in (7)].
The excellent safety profile of MVA, which stems from its repli-
cation deficiency in human cells, has been proven in many clinical
trials, including vaccination of immune-compromised individu-
als, and during the smallpox eradication campaign in the 1970s,
when 120,000 people were vaccinated with MVA (8). Since then,
many different recombinant MVA vaccines have been generated
and tested for the ability to immunize animals and humans against
infectious (e.g., HIV, malaria) and non-infectious (e.g., prostate
cancer) diseases. Its proven safety and good immunogenicity thus
makes MVA a prime candidate for a T and B cell-inducing vaccine
vector.
Classically, vaccine development has focused on the induction
of neutralizing antibodies. In recent years, however, T cells, espe-
cially CD8 T cells, have moved into the focus of vaccinologists.
This paradigm shift stems from an increasing amount of data,
showing the need for high amounts of multi-functional CD8 T
cells to clear or protect against pathogens such as HIV/SIV (9, 10),
Ebola virus (11), human papillomavirus (HPV) (12), hepatitis
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C virus (HCV) (13), and Plasmodium falciparum, the causative
agent of malaria (14, 15). Furthermore, adoptive transfer exper-
iments have demonstrated the therapeutic potential of CD8 T
cells in treating cancer (14, 16). This increased awareness of the
importance of CD8 T cells has spurred more basic science aimed
at better understanding T cell biology. Even though not all factors
and mechanisms governing cytotoxic T-lymphocyte (CTL) expan-
sion and memory differentiation are understood in all details,
it is believed that expansion, development of effector functions,
and ultimately, differentiation into memory cells are mainly deter-
mined during the first few days after antigen encounter (17). In a
simplistic view, antigen recognition via the T cell receptor (TCR)
(signal 1) activates the T cell and co-stimulation via CD28 and
CD80/CD86 (signal 2), and the secretion of cytokines such as
interleukin-12 (IL-12) and interferon-α (IFN-α) (signal 3) ensure
the efficient generation of effector and memory CTLs. However,
after pathogen encounter a plethora of additional stimulatory and
inhibitory molecules are induced, creating a specific inflamma-
tory environment, which further influences quality and quantity
of CTL responses (18).
Among those molecules, members of the tumor necro-
sis factor receptor/tumor necrosis factor (TNFR/TNF) super-
family are well known for their T cell shaping properties.
This family includes, among others, CD27/CD70, CD30/CD30L,
CD40/CD40L, OX40/OX40L, 4-1BB/4-1BBL, GITR/GITRL, and
Fas/FasL. The role of CD70, OX40L, and 4-1BBL for primary and
secondary T cell responses was investigated in a broad range of
infectious disease models (19–21). Interestingly, the up-regulation
of co-stimulatory molecules (including CD80, CD86, CD70, 4-
1BBL, and OX40L) on dendritic cells (DCs) can be induced by
combined Toll-like receptor (TLR)/CD40-stimulation (22). Fur-
thermore, TLR/CD40 ligation also induces the expression of pro-
inflammatory cytokines, including IL-12p70, by DCs in vivo (23).
Thus, CD40 can be regarded as a master-switch for DC activation.
While CD40 is constitutively expressed on many cell types, includ-
ing B cells, macrophages, and DCs, its ligand CD40L is predom-
inantly expressed on activated CD4 T cells (24, 25). The cognate
interaction between DCs and CD4 T cells early after infection or
immunization ‘licenses’ DCs to prime CD8 T cell responses (26,
27). DC licensing results in the up-regulation of co-stimulatory
molecules, increased survival and better cross-presenting capabil-
ities of DCs. This process is mainly mediated via CD40/CD40L
interaction (28, 29), but CD40/CD40L-independent mechanisms
also exist (30, 31). Interestingly, the direct interaction between
CD40L expressed on DCs and CD40 expressed on CD8 T cells
has also been suggested, providing a possible explanation for the
generation of helper-independent CTL responses (32).
Several studies indicate that agonistic anti-CD40 antibody (Ab)
may be useful as a vaccine adjuvant. In addition, recombinant
AdV (33) and VV (34) encoding CD40L have been created that
showed superior immunogenicity in vitro and in vivo compared
to non-adjuvanted viruses. Based on these data, the central role
of CD40/CD40L co-stimulation for CD8 T cell responses and the
good CTL-inducing capacities of MVA together with its favor-
able safety profile, we constructed a recombinant MVA expressing
CD40L and the model antigen ovalbumin (OVA). In vitro and
in vivo analyses revealed significantly enhanced DC activation
and cytokine production (including high levels of IL-12p70) after
treating cells or mice with MVA-OVA-CD40L. This effect was
entirely dependent on de novo CD40L gene expression, partly
contradicting previous results (34). While Ab responses were not
increased, immunization with MVA-OVA-CD40L led to strongly
enhanced primary and memory CD8 T cell responses. Of note, one
immunization with MVA-OVA-CD40L induced the same number
of antigen-specific CTL as two immunizations with MVA-OVA.
Importantly, not only the quantity but also the quality of the CTL
response was improved, as revealed by intracellular cytokine stain-
ing and in vivo killing activity. Finally, the superior T cell response
directly translated into better protection against a fatal virus infec-
tion (mousepox) in B cell deficient mice. These results highlight
the potential of a CD40L-adjuvanted MVA to induce rapidly strong
antigen-specific multi-functional CD8 T cell responses. Thus,
recombinant MVA-CD40L is a prime candidate for the develop-
ment of prophylactic and therapeutic vaccines against diseases
such as cancer, HIV/AIDS, Ebola and Marburg hemorrhagic fever,
malaria and hepatitis C, and also for emergency vaccinations in
cases of bioterrorism attacks.
RESULTS
MVA-INDUCED CD8 T CELL RESPONSES ARE AMPLIFIED BY AN
AGONISTIC ANTI-CD40 ANTIBODY
The combination of a TLR-ligand and a CD40 agonist has been
shown to synergistically enhance antigen-specific CD4 and CD8
T cell responses after protein immunization (35, 36). Because of
the TLR-stimulating properties of MVA (37, 38), we hypothesized
that co-administration of MVA and a CD40 agonist might lead
to enhanced CD8 T cell responses. Therefore, we first set out
to evaluate whether MVA-induced CD8 T cell responses can be
amplified by an agonistic Ab to murine CD40. Mice were immu-
nized with MVA-OVA (hereafter referred to as rMVA), rMVA
mixed with anti-CD40 Ab, or OVA protein combined with anti-
CD40 Ab. MHC class I (H-2Kb) dextramers loaded with either
B820–27- or OVA257–264-peptide were used to detect MVA- and
OVA-specific CD8 T cell responses, respectively (Figure 1A).
Flow cytometric analysis of peripheral blood lymphocytes (PBL)
revealed that rMVA immunization induced B8- and OVA-specific
CD8 T cell responses. These responses were enhanced∼7- and∼3-
fold, respectively, by anti-CD40 Ab (Figure 1B). OVA/anti-CD40
immunization, in contrast, did not lead to a detectable antigen-
specific CD8 T cell response. In order to verify that our findings
with the model antigen OVA are transferable to pathogen-derived
antigens, we repeated the above experiment using recombinant
MVA encoding the glycoprotein (GP) from Zaire Ebola virus
(rMVA-GP). Ebola GP-specific CD8 T cells were detected by intra-
cellular cytokine staining after re-stimulation with the H-2Kk
restricted peptide GP577–584 (39). Again, we could observe a sig-
nificantly (p< 0.05) enhanced GP-specific CD8 T cell response
in the spleen of mice immunized with rMVA-GP+ anti-CD40
(Figure 1C).
CONSTRUCTION AND IN VITRO CHARACTERIZATION OF rMVA-CD40L
In order to take advantage of the large transgene acceptance of
MVA, we decided to create a recombinant MVA encoding both,
the neo-antigen and the co-stimulatory molecule. To this end,





























































FIGURE 1 | CD40 co-stimulation increases CTL responses to rMVA
encoded antigens but not to a protein antigen. C57BL/6 mice were
immunized with rMVA, rMVA+ anti-CD40 mAb, or OVA protein+ anti-CD40
mAb. B8- and OVA-specific CD8 T cells were visualized by MHC class I
dextramer staining. (A) Density plots illustrate the frequency of B8- and
OVA-specific CTL in the blood on day 7 (gated on CD8+ PBL). Numbers
indicate the percentage of CD8+ dextramer+ T cells among PBL. A kinetic
analysis of B8- and OVA-specific CTLs is shown in (B). CTL responses to B8
and OVA were drastically enhanced by co-injection of rMVA and anti-CD40
mAb. Note, that no detectable CTL response was generated after
immunization with OVA protein and anti-CD40 antibody. (C) Similar to the
above described experiment, CBA/J (H-2k) mice were immunized with
rMVA-GP encoding the glycoprotein of Zaire Ebola virus± anti-CD40 mAb.
The GP-specific CD8 T cell response was measured 7 days later by
intracellular cytokine staining. Shown is the mean percentage±SEM of
IFN-γ+ GP-specific CD8 T cells in the spleen. Data are representative of four
mice per group.
a CD40L expression cassette including the recently described
early/late hybrid promoter (pHyb) (40) and the cDNA sequence
of murine CD40L was inserted into a recombinant MVA express-
ing OVA under the control of the early/late synthetic promoter
(pS) (41) (Figure 2). This promoter choice guaranteed a simulta-
neous expression of antigen and co-stimulus. The model antigen
FIGURE 2 | Schematic representation of rMVA and rMVA-CD40L.
Recombinant MVA encoding OVA alone or OVA together with murine
CD40L were generated as described in Materials and Methods. OVA
expression is controlled by the early/late synthetic promoter (pS) and CD40L
expression by the recently described early/late hybrid promoter (pHyb) (40).
OVA instead of Ebola GP was used because more analytical tools
are available for OVA and the above described experiments sug-
gested that OVA based findings were likely to be applicable to other
neo-antigens as well.
The expression of OVA and CD40L was verified by trans-
ducing FLT3-L bone marrow culture derived DCs (FLDCs) with
rMVA or rMVA-CD40L. OVA expression was measured by using
the 25-D1.16 Ab that specifically detects H-2Kb/OVA257–264 com-
plexes (42). As shown in Figure 3A (upper row), OVA expression
was readily detected after 3 h and continued to increase during
the observation period of 9 h. While there was no difference
in OVA expression in rMVA or rMVA-CD40L transduced cells,
CD40L was exclusively expressed in cells transduced with the latter.
Importantly, H-2Kb/OVA257–264 complexes and CD40L appeared
synchronously on the cell surface of transduced FLDCs, ensur-
ing the isochronic availability of antigen and co-stimulus. The
same cells were also analyzed for expression of the two activa-
tion markers CD86 and CD80. rMVA transduced FLDCs showed
only weak signs of activation after 9 h compared to untreated cells
(Figure 3A; bottom row). In contrast, the geometric mean fluo-
rescence intensity (GMFI) of CD86 and CD80 was 3- to 4-fold
higher after 9 h in rMVA-CD40L transduced cells compared to
rMVA transduced cells. In order to further compare the in vitro
immunogenicity of the two constructs, the amount of secreted
cytokines in the supernatant of transduced FLDCs was mea-
sured. Both, rMVA and rMVA-CD40L transduced cells secreted
IL-6 and IFN-α above background levels, with far higher lev-
els in rMVA-CD40L transduced cells (Figure 3B). TNF-α and
IL-12p70, however, were strongly expressed exclusively by rMVA-
CD40L transduced FLDCs. Thus, the addition of CD40L into
rMVA did not change OVA-antigen expression but improved its
immunogenicity in vitro.
HEIGHTENED DC ACTIVATION AND INNATE CYTOKINE PRODUCTION
IN VIVO AFTER IMMUNIZATION WITH rMVA-CD40L
To gain insight into the immunostimulatory properties of the
two vaccine vectors in vivo, mice were intravenously (i.v.) inoc-
ulated with rMVA and rMVA-CD40L. Six hours after injection,
mice were bled for serum cytokine analyses. While there were
no differences in expression of CCL7 and IL-18, rMVA-CD40L
induced significantly higher levels of CCL2, IL-6, TNF-α, IFN-α,
IL-12p70, and IFN-γ, with the latter two not detectable in serum
of rMVA immunized mice (Figure 4). Of note, IL-12p70 levels
after rMVA-CD40L immunization were∼10-fold higher than after
injection of the prototypic IL-12 inducer CpG1668 (2936± 1046
vs. 292± 31 pg/ml). Similar to our in vitro analyses, DC activation
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FIGURE 3 |Transduction of FLDCs in vitro with rMVA-CD40L leads to
superior DC activation and cytokine secretion. In vitro generated FLDCs
were transduced with rMVA or rMVA-CD40L (MOI2). (A) Three, six, and
nine hours after transduction DCs were analyzed for OVA (H-2Kb/OVA257–264
complexes) and CD40L expression and the activation markers CD86 and
CD80. Note that OVA expression is not different between rMVA and
rMVA-CD40L. (B) At the same time points as in (A) supernatants were
analyzed for IL-6, IFN-α, TNF-α, and IL-12p70 by a cytometric bead assay.
Note that IL-12p70 and TNF-α were only detectable after transduction with
rMVA-CD40L but not rMVA. Data are representative of at least two
independent experiments. Shown is the mean of duplicate samples.
in vivo was also monitored. CD80 and CD86 expression by
conventional DCs (cDCs) was increased after rMVA immuniza-
tion with the peak at 24 h (Figure 5A). Both, CD80 and CD86, were
expressed at a significantly higher level after injection of rMVA-
CD40L. In order to confirm that the enhanced immunogenicity
of rMVA-CD40L is due to the insertion of CD40L, wild-type
(wt) C57BL/6 mice were immunized either with rMVA or rMVA-
CD40L, CD40−/− mice were immunized with rMVA-CD40L,
and CD86 expression by cDCs was measured again after 24 h.
While wt DCs expressed higher levels of CD86 following rMVA-
CD40L immunization compared to rMVA immunization, there
was no enhanced expression by DCs isolated from CD40−/− mice
(Figure 5B). Similarly, the cytokine expression pattern after 6 h
was comparable between rMVA immunized wt mice and rMVA-
CD40L immunized knock-out (ko) mice (Figure 5B). Because
Bereta et al. suggested that CD40L might be present in recom-
binant VV virions (34), it was possible that this might also be
true for our vector. To test this possibility, we inactivated rMVA-
CD40L by psoralen/UV treatment and measured serum cytokine
levels 6 h after immunization. In contrast to active rMVA-CD40L,
no IL-12p70 was detected in the serum of mice treated with inacti-
vated virus (Figure 5C). Taken together, these data confirmed the
enhanced capacity of rMVA-CD40L to activate innate immunity
and proved that the observed effect was strictly dependent on inter-
action between CD40 and virally encoded and newly expressed
CD40L.
rMVA-CD40L IMMUNIZATION INDUCES HIGH NUMBERS OF
ANTIGEN-SPECIFIC CD8 T CELLS AND FASTER MEMORY
DIFFERENTIATION
The strong up-regulation of co-stimulatory molecules on DCs and
the induction of high levels of T cell instructing cytokines (e.g., IL-
12p70) following rMVA-CD40L immunization suggested that this
vector might induce superior CTL responses, too. Therefore, after
having assessed innate immunity in vitro and in vivo, the analyses
were extended to examine T cell responses after rMVA-CD40L
immunization. To this end, C57BL/6 mice were injected with
rMVA or rMVA-CD40L and the frequency of B8- and OVA-specific
CD8 T cells in blood over time was measured. In mice of both
groups, specific CD8 T cells became detectable on day 4 and peaked
on day 7 after the first immunization (Figure 6A). In line with the
pilot experiment (see Figure 1), the frequency at the peak of the
primary response of B8- and OVA-specific CTLs was ∼5- and
∼2-fold higher, respectively, after rMVA-CD40L immunization.
As expected, both T cell populations increased substantially after
the boost on day 35 and once again antigen-specific CD8 T cell fre-
quencies were higher in rMVA-CD40L immunized mice. Notably,
a single immunization with rMVA-CD40L resulted in the same fre-
quency of B8-specific T cells (∼26% of PBL) as two immunizations
with rMVA. In order to gain insight into the effect of additional
CD40L stimulation on memory differentiation, we further ana-
lyzed the expression of the IL-7 receptor α chain (IL-7Rα, CD127)
on antigen-specific CD8 T cells. Surface expression of CD127 on
activated CD8 T cells is used as a marker to distinguish between
effector and memory T cells (43, 44) and CD127high memory CD8
T cells have been correlated with better protection against bacte-
rial challenge (44). Interestingly, at all time points analyzed B8-
and OVA-specific CD8 T cells in rMVA-CD40L immunized mice
had higher GMFIs of CD127 (Figure 6B). The differences were
not statistically significant at all days, however. The higher GMFI
was a result of both, more CD127high cells and a higher CD127
expression on a per cell basis. The difference between the two
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FIGURE 4 | Enhanced systemic cytokine levels after injection of
rMVA-CD40L. C57BL/6 mice were treated with PBS, rMVA, or
rMVA-CD40L. Six hours after injection, serum cytokine levels were
determined by a cytometric bead assay. Note that IL-12p70 was only
detectable after rMVA-CD40L injection. IFN-γ levels were low to
undetectable after rMVA immunization. Results are compiled from three
independent experiments. Circles denote individual mice and bars the
mean of all mice per group.
groups became most prominent after the second immunization.
Thus, rMVA-CD40L immunization not only leads to enhanced
CTL responses but also to faster memory differentiation.
HIGHER EXPRESSION OF IL-2Rα AND IL-7Rα ON T CELLS AND FASTER
PROLIFERATION AFTER rMVA-CD40L IMMUNIZATION
The strongly enhanced CD8 T cell response after rMVA-CD40L
immunization prompted us to investigate in more detail the CD8 T
cells generated early after priming. Enhanced CD8 T cell numbers
can be the result of faster proliferation, less apoptosis, or a com-
bination of both. Proliferation and survival in turn are regulated,
at least in part, by cytokines of the IL-2 family (IL-2, IL-4, IL-7,
IL-9, IL-15, and IL-21) (45). Especially, enhanced signaling via the
IL-2 receptor leads to stronger expansion of antigen-stimulated
CD8 T cells (46–48). Therefore, we initially measured expression
of CD25 (IL-2Rα), CD127 (IL-7Rα), and the anti-apoptotic mol-
ecule Bcl-2 on B8-specific CD8 T cells 5 days after immunization
with rMVA or rMVA-CD40L. B8-specific CD8 T cells in rMVA-
CD40L immunized animals displayed higher expression of CD25
and CD127 but not of Bcl-2 compared to rMVA immunized mice
(Figure 7A). In order to measure cell proliferation, the thymi-
dine analog EdU was administered intravenously on day 5 after
immunization and the spleens were excised 1 hour later. As shown
in Figure 7B, EdU was incorporated into the DNA of CD4 and
CD8 T cells. No EdU uptake was observed in naïve mice (data
not shown). The percentage of EdU+ CD4 and CD8 T cells was
∼2.5 times higher in rMVA-CD40L than in rMVA immunized
mice. Also, significantly more B8-specific CD8 T cells had taken
up EdU within 1 h (27.6± 0.9% vs. 21.6± 1.3%; p< 0.005). Fur-
thermore, we determined the amount of incorporated EdU on a
per cell basis by measuring the GMFI of EdU+ cells. All inves-
tigated T cell populations (CD4, CD8, and B8-specific CD8) in
rMVA-CD40L immunized mice showed drastically higher GMFIs
of EdU, indicating a faster cell cycle. Taken together, both, higher
expression of CD25 and CD127 and more and faster proliferat-
ing T cells, were observed after immunization with rMVA-CD40L.
Because IL-12 is known to influence the memory potential of
CD8 T cells (34, 49), we sought to analyze the memory related
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FIGURE 5 | Enhanced DC activation in vivo after rMVA-CD40L
immunization. C57BL/6 mice were treated with PBS, rMVA, or
rMVA-CD40L. (A) Six, twenty four, and forty eight hours after injection splenic
DCs were analyzed for expression of the activation markers CD80 and CD86.
Similar to in vitro transduced DCs (see Figure 3), splenic DCs were more
strongly activated by rMVA-CD40L. The peak of activation was at 24 h post
immunization. (B) In order to test whether the enhanced immunogenicity of
rMVA-CD40L is dependent on the interaction of CD40 and virally encoded
CD40L, we immunized CD40+/+ C57BL/6 mice with rMVA or rMVA-CD40L
and CD40−/− mice with rMVA-CD40L. Serum concentration of IL-12p70 was
determined 6 h after injection and CD86 expression was analyzed on splenic
DCs after 24 h. (C) C57BL/6 mice were immunized with active or
UV/psoralen-inactivated rMVA and rMVA-CD40L. Serum concentration of
IL-12p70 was determined 6 h after injection and CD86 expression was
analyzed on splenic DCs after 24 h. Shown is the mean±SEM of three to six
mice per group.
phenotype of B8 CD8 T cells. As shown in Figure 7C, 12.2± 1.6%
of B8-specific CD8 T cells had the phenotype of short lived effec-
tor cells (SLECs, which are CD127− KLRG-1+) 7 days after rMVA
immunization, while 20.5± 1.1% displayed this phenotype after
rMVA-CD40L immunization. In the latter group, most cells were
double positive for CD127 and KLRG-1 (55± 3%) – a popula-
tion described to display an intermediate recall potential (50) and,
recently, to form a highly protective effector-like memory subset
(51). The percentage of memory precursor effector cells (MPECs,
which are CD127+ KLRG-1−) and early effector cells (EECs,which
are CD127− KLRG-1−) was higher in rMVA immunized mice
(43.8± 3.4 and 19.7± 2.3%, respectively). Thus, integration of
CD40L into rMVA clearly influences cell proliferation and memory
differentiation of CD8 T cells.
INCREASED NUMBERS AND FUNCTIONALITY OF ANTIGEN-SPECIFIC
CD8 T CELLS AFTER rMVA-CD40L IMMUNIZATION
T cell mediated protection is the result of increased numbers of
antigen-specific CD8 T cells that are poised to rapidly secrete
cytotoxic molecules (e.g., perforin, granzyme B) and cytokines
(e.g., IFN-γ, TNF-α). Therefore, after having assessed increased
frequencies after rMVA-CD40L immunization we set out to
analyze the absolute number and functionality of effector and
memory B8- and OVA-specific CD8 T cells in the spleen. To this
end, B8- and OVA-specific CD8 T cells were enumerated by MHC
class I dextramer staining and intracellular cytokine staining at
day 7 after one immunization and at day 104 after two immu-
nizations. Increased frequencies in the blood after rMVA-CD40L
immunization translated into higher absolute numbers of B8- and
OVA-specific CD8 T cells in the spleen at day 7 (Figures 8A,B,
left panel). More IFN-γ and TNF-α producing effector CD8 T
cells were also detected for both antigens (Figures 8A,B, middle
panel). A higher functional capacity after rMVA-CD40L immu-
nization was revealed by relative more IFN-γ+ TNF-α+ cells
(Figures 8A,B, right panel). At this time point, there was no
difference in IL-2 production between the two groups. Analy-
sis of memory T cells at day 104 (=day 69 after the second
immunization) revealed only marginal differences in absolute
numbers of B8- and OVA-specific CD8 T cells between rMVA
and rMVA-CD40L immunized mice (Figures 9A,B, left panel).
Also, the frequencies of IFN-γ and TNF-α producing memory
cells were similar (Figures 9A,B, middle panel). In contrast to
effector cells, however, more rMVA-CD40L-induced memory CD8
T cells produced IL-2 upon re-stimulation with B8 and OVA
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FIGURE 6 | Increased CD8T cell response after rMVA-CD40L
immunization. C57BL/6 mice were immunized with rMVA and
rMVA-CD40L on day 0 and 35. The primary and secondary B8- and
OVA-specific CD8 T cell response was quantified by dextramer staining of
PBL at the indicated time points as shown in Figure 1A. (A) The kinetic
analysis shows the mean percentage±SEM of CD8+ dextramer+ T cells
among PBL. (B) B8- and OVA-specific CD8 T cells were also analyzed flow
cytometrically for surface expression of CD127. Data are represented as the
mean±SEM GMFI. Data are representative of five mice per group and two
independent experiments.
peptides (Figures 9A,B, middle panel). Importantly, mice that
were immunized with rMVA-CD40L had ∼2-fold more triple
cytokine positive (IFN-γ, TNF-α, IL-2) antigen-specific CD8 T
cells (Figures 9A,B, right panel). Those results demonstrated that
immunization with rMVA-CD40L induced more multi-functional
effector and memory CD8 T cells than immunization with rMVA.
Since multi-functional T cells have been correlated with better pro-
tection against parasites, bacteria and viruses (9, 52–54) these data
suggest that this vaccine vector might induce superior protection.
IMMUNIZATION WITH rMVA-CD40L CONFERS PROTECTION
INDEPENDENTLY OF ANTIBODIES
In light of the astonishing strong CD8 T cell response after immu-
nization with rMVA-CD40L we also wanted to evaluate whether
immunization with this novel vaccine vector provides better pro-
tection in an infection model. First, we determined the cytolytic
activity of antigen-specific memory CD8 T cells by an in vivo CTL
assay at day 56 after a single immunization. The killing activity
was analyzed 4 h after target cell transfer and revealed 54 com-
pared to 97 percent specific lysis (PSL) of B820–27-loaded target
cells and 11 compared to 43 PSL of OVA257–264-loaded target
cells for rMVA and rMVA-CD40L immunized mice, respectively
(Figure 10).
In order to reveal the consequences of the improved CD8 T cell
response after rMVA-CD40L immunization in a highly relevant
infection model, we choose ectromelia virus (ECTV) infection of
mice (mousepox). Mousepox is considered to be the best small
animal model for human smallpox (38, 55). Because prophylactic
immunization of wt mice with MVA already provides full pro-
tection against VV or ECTV challenge via antibodies (56), a T
cell dependent and Ab independent challenge model was used
(57, 58). To this end, B cell deficient JHT mice were immunized
with rMVA or rMVA-CD40L and then challenged approximately
2 months later with a lethal dose of ECTV. B8-specific CD8 T cell
responses were confirmed to be similar in JHT and wt mice (com-
pare Figures 6 and 11A). While 87% of mice immunized with
rMVA developed severe symptoms of ECTV infection, including
necrotic tails, swollen and necrotic paws, and skin lesions, and
either died or had to be euthanized, only 47% of the rMVA-CD40L
immunized mice developed infection symptoms during an obser-
vation period of 100 days (Figure 11B). Also, the onset of disease
was earlier in rMVA immunized than in rMVA-CD40L immu-
nized mice. Because the frequency of peripheral B8-specific CD8
T cells was similar in mice that were immunized twice with rMVA
and mice that were immunized only once with rMVA-CD40L
(Figure 6), we tested whether JHT mice were protected after two
rMVA immunizations. Indeed, those mice did not become symp-
tomatic and remained healthy throughout the observation period.
These data suggest that the heightened and qualitatively improved
CD8 T cell response after a single rMVA-CD40L immunization
leads to a better virus control after a lethal virus challenge even in
the absence of antibodies.
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FIGURE 7 | rMVA-CD40L immunization influences the phenotype and
the proliferation rate of CD8T cells. C57BL/6 mice were immunized with
rMVA and rMVA-CD40L. Five days later expression of CD25, CD127, and
Bcl-2 in splenic B8-specific CD8 T cells was analyzed flow cytometrically. (A)
Bars represent the mean±SEM GMFI (gated on B8-dextramer+ CD8 T
cells). In order to measure cell proliferation, mice were treated with the
thymidine analog EdU on day 5 after immunization. EdU incorporation into
splenic T cells was determined flow cytometrically after 1 h. (B) The
percentage and GMFI of EdU+ CD4, CD8, and B8-specific T cells are shown
as the mean±SEM. (C) depicts the relative frequencies of CD127+
KLRG-1−, CD127+ KLRG-1+, CD127− KLRG-1+, and CD127− KLRG-1− cells
among all splenic B8-specific CD8 T cells on day 7 after immunization. Data
are representative of five mice per group and at least two independent
experiments.
DISCUSSION
It is generally agreed upon that protection against major human
pathogens such as HIV, Mycobacterium tuberculosis and Plasmod-
ium falciparum will require the induction of very large memory
CD8 T cell responses. Despite some progress in recent years, so far
no vaccines against these pathogens exist. It is this unmet medical
need that let us design a recombinant vaccine vector targeted at
enhancing both the magnitude and functionality of primary and
memory CD8 T cell responses.
Pathogen-induced T cell responses start in secondary lym-
phoid organs such as lymphnodes and spleen, where naïve T
cells are primed by antigen-presenting cells (APCs), preferentially
DCs. Here, DCs present antigen via MHC class I and further
provide co-stimulatory signals and inflammatory cytokines. The
integration of these variegated signals is essential to achieve max-
imal T cell expansion and differentiation. Thus, the magnitude
and functionality of responding CD8 T cells and the ensuing
development of memory cells is largely programed in the first
few days after pathogen encounter by tightly controlled DC-T
cell interactions (17). After priming, CD8 T cells continue to
encounter a plethora of signals that further shape their fate (18).
Many of the factors that influence CTL responses have been elu-
cidated in recent years, providing vaccinologists with more tools
and knowledge for a rational development of therapeutics and
vaccines.
In this study, we used the TNFSF member CD40L for genetic
adjuvantation of a recombinant MVA vaccine vector. The strong
stimulatory activity of CD40/CD40L in innate and adaptive
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FIGURE 8 | Quantitative and qualitative improvement of primary CD8T
cell responses after immunization with rMVA-CD40L. C57BL/6 mice
were immunized with rMVA or rMVA-CD40L. B8- (A) and OVA- (B) specific
CD8 T cell numbers in the spleen were determined by MHC I dextramer
staining on day 7 after immunization (left panel). IFN-γ, TNF-α, and IL-2
production was analyzed by intracellular cytokine staining after standard 6 h
in vitro re-stimulation with B820–27 and OVA257–264 peptides (middle panel). Pie
charts denote the fraction of IFN-γ+ cells expressing IFN-γ alone (violet),
IFN-γ and TNF-α (green), IFN-γ and IL-2 (blue), and IFN-γ, TNF-α, and IL-2
(red). Note the increased percentage of IFN-γ/TNF-α double producer cells
in rMVA-CD40L immunized mice (green area). Thus, in comparison to rMVA
rMVA-CD40L immunization leads to functionally improved primary effector
CD8 T cells. Data are representative of five mice per group and two
independent experiments.
immune responses makes CD40L a prime candidate for this
purpose. Recombinant CD40L-encoding vaccinia viruses were
already generated in the mid-1990s by Ruby et al. (59). This study,
however, was designed to study the immunobiology of CD40L
and not its applicability as a vaccine component. Based on the
finding that nude and SCID mice could clear an infection with
CD40L-expressing VV largely independently of IFN-γ and TNF-
α, Ruby et al. postulated an antiviral activity for CD40L itself.
While this first study focused on virus clearance, more recent
studies investigated the immune properties of CD40L-adjuvanted
poxvirus vectors in vitro and in vivo (34, 60, 61). The results from
Liu et al. showed that co-immunization of ALVAC-HIV-1 (an
attenuated canarypox vector) and a CD40L-expressing ALVAC led
to 2-fold increased HIV-1-specific CD8 T cell responses in mice
(61). Similar to this study, we could enhance vector- (B820–27) and
transgene- (OVA257–264 and Zaire Ebola virus GP577–584) specific
CD8 T cell responses by co-immunization of rMVA and anti-CD40
mAb. In contrast to the study by Liu et al., we observed strong
CD8 T cell responses already after a single immunization, even
with non-adjuvanted rMVA. As shown before, OVA protein and
anti-CD40 co-immunization did not lead to a detectable primary
CTL response (22).
Because we hypothesized that the adjuvant effect is strongest
when CD40L and the transgene are expressed synchronously by
the same cell, we went on to construct a recombinant MVA with
OVA and CD40L under the control of early/late promoters. It
was shown previously that early transgene expression is necessary
for the induction of optimal CTL responses (62). Initial in vitro
analyses showed that integration of CD40L into rMVA drastically
enhanced expression of CD80 and CD86 by FLDCs. Additionally,
FLDCs transduced with rMVA-CD40L produced more IL-6 and
IFN-α and secreted TNF-α and IL-12p70, cytokines that were not
detected in the supernatant of rMVA treated FLDCs. These data
are in line with previous studies with UV/psoralen-inactivated VV
(34, 60) and ALVAC (61). In contrast to Bereta et al. (34), we did
not find evidence for CD40L protein in viral particles (Figure 5).
The reason for this discrepancy is not clear, but could be due to dif-
ferential virus purification protocols that might influence the final
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FIGURE 9 | Qualitative improvement of memory CD8T cell responses
after immunization with rMVA-CD40L. C57BL/6 mice were immunized
on day 0 and 35 with rMVA or rMVA-CD40L. B8- (A) and OVA- (B) specific
CD8 T cell numbers in the spleen were determined by MHC I dextramer
staining on day 104 (left panel). IFN-γ, TNF-α, and IL-2 production was
analyzed by intracellular cytokine staining after standard 6 h in vitro
re-stimulation with B820–27 and OVA257–264 peptides (middle panel). Pie
charts denote the fraction of IFN-γ+ cells expressing IFN-γ alone (violet),
IFN-γ and TNF-α (green), IFN-γ and IL-2 (blue), and IFN-γ, TNF-α, and IL-2
(red). Note the increased percentage of IFN-γ/TNF-α/IL-2 triple producer
cells in rMVA-CD40L immunized mice (red area). Thus, in comparison to
rMVA rMVA-CD40L immunization leads to functionally improved memory
CD8 T cells. Data are representative of five mice per group and two
independent experiments.
composition of the virus suspension (63), or differences between
VV and MVA.
Importantly, our in vitro findings could be directly trans-
lated in vivo, with increased DC activation and heightened
cytokine secretion after i.v. immunization. Especially with the
strong expression of CD80/86 (signal 2) by splenic DCs and the
high amount of IL-12p70 (signal 3) rMVA-CD40L immunization
induced an optimal milieu for CD8 T cell priming and memory
formation. Indeed, quality and quantity of rMVA-CD40L induced
CD8 T cell responses were superior to those induced by rMVA
immunization. Therefore, it seems likely that the cooperative
effect of CD80/86 and IL-12 co-stimulation is largely responsi-
ble for the enhanced CTL response. The synergistic effect of both
molecules was demonstrated in vitro (64) and also in an experi-
mental antitumor model in mice using recombinant VV (65, 66).
A further potent co-stimulatory molecule, namely CD70, was also
up-regulated on splenic DCs after rMVA-CD40L immunization
(data not shown). Because rMVA-CD40L immunization leads to
both, high levels of systemic IL-12 and strong up-regulation of
CD80/86, it obviates the need for exogenous IL-12 administration
or the construction of CD80, IL-12p35, IL-12p40 triple recom-
binants as done previously in the studies by Carroll et al. and
Rao et al. (65, 66). Another possible explanation for the enhanced
immunogenicity of rMVA-CD40L could be a direct interaction
between CD40 on CD8 T cells and CD40L expressed by DCs, as
described by Johnson et al. (32).
In recent years, a highly inflammatory milieu was correlated
with enhanced formation of short lived effector cells (SLECs,
CD127− KLRG-1+) at the expense of memory precursor effec-
tor cells (MPECs, CD127+ KLRG-1−), thus limiting the amount
of long lived memory cells (49, 50, 67). Detailed studies revealed
this differentiation to be dependent on the ratio between the
transcription factors T-bet and Eomesodermin (Eomes) (49, 68).
CD80 co-stimulation and IL-12 signaling were revealed to be
major drivers of enhanced T-bet expression via the mTOR path-
way (69). Since we detected higher expression of CD80, CD86,
and IL-12p70 by DCs stimulated by rMVA-CD40L in vitro and
in vivo, we expected a shift of primary CTLs toward a SLEC
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FIGURE 10 | Heightened CTL activity in rMVA-CD40L immunized mice.
In order to characterize the lytic activity of B8- and OVA-specific CD8 T cells,
an in vivo CTL assay was performed on day 56 after immunization.
Unpulsed (CFSElow), B820–27-peptide pulsed (CFSEhigh) and
OVA257–264-peptide pulsed (eFluor670high) splenic target cells were injected
into rMVA and rMVA-CD40L immunized mice. Four hours post-transfer the
ratio of unpulsed and peptide pulsed target cells was determined and the
percent specific lysis calculated. Values represent mean±SEM specific
lysis of target cells of four mice per group. The experiment was performed
twice with similar results.
phenotype. Surprisingly, antigen-specific CD8 T cells at day 7
after rMVA-CD40L immunization were largely CD127+ KLRG-
1+, whereas the largest CTL population after rMVA immunization
was CD127+ KLRG-1− (Figure 7C). Thus, the priming under
strong stimulatory and inflammatory conditions (i.e., after rMVA-
CD40L immunization) led to more KLRG-1+ CD8 T cells but did
not repress CD127 expression, because B8- and OVA-specific CD8
T cells had higher surface expression of CD127 after rMVA-CD40L
than after rMVA immunization (Figures 6 and 7). Interestingly,
CD127+ KLRG-1+ CD8 T cells are usually found in secondary
and tertiary memory responses after multiple infections or immu-
nizations (50, 70). KLRG-1+ CD8 T cells were initially described
to have a severely diminished potential to proliferate after anti-
gen re-encounter (71). Adding CD127 for further subdivision
of KLRG-1+ cells, Obar et al. described an intermediate recall
potential for CD127+ KLRG-1+ double positive CD8 T cells,
whereas CD127− KLRG-1+ cells were most drastically impaired
in their ability to expand after Ag stimulation (50). Interestingly,
Olson et al. described recently an effector-like memory subset
with a CD27lo CD43lo CD62Llo KLRG-1hi CD127int pheno-
type (51). This CD8 T cell subset displayed enhanced capacity
to eliminate Listeria and was preferentially localized to the red
pulp of the spleen. It will be interesting to test the CD127+
KLRG-1+ CD8 T cells induced by rMVA-CD40L immunization
for the expression of CD27 and CD43 in order to find out whether
they resemble the cells described by Olson et al. Besides inflam-
mation (i.e., IL-12) the expression of CD25 and sustained IL-2
signaling during expansion were linked to the development of
SLECs (48, 72, 73). Therefore, our data showing higher CD25
expression on B8-specific CD8 T cells after rMVA-CD40L immu-
nization would, once again, favor the development of SLECs. The
dominance of CD127+ KLRG-1+ double positive CD8 T cells at
the peak of the primary response after rMVA-CD40L immuniza-
tion is probably a result of the combination of the high levels
of IL-12p70 and enhanced IL-2 signaling. In the defined cell-
culture setting used by Pipkin et al. inflammatory signals (i.e.,
CpG and IL-12) enhanced expression of CD25 and T-bet but
counteracted IL-2-mediated repression of CD127 (73). The higher
CD25 expression on B8-specific CD8 T cells in rMVA-CD40L-
immunized mice, in comparison to rMVA immunized mice, is
a likely explanation for more and faster proliferating T cells in
this group, because IL-2 signaling is directly linked to sustained
proliferative expansion of CD8 T cells (46–48). Taken together,
our data support a model in which combined TLR- and CD40-
stimulation of DCs after encounter with rMVA-CD40L increases
the expression of CD80/CD86 co-stimulatory molecules and IL-
12p70. Signaling via the CD28:CD80/86 pathway then causes
IL-2 expression perhaps by CD4 T cells (74), which regulates
CD25 expression on CD8 T cells (75). The early expression of
IL-12p70 in our experiments and its demonstrated linkage with
TCR engagement (76) suggest an influence of this cytokine on
effector T cell generation during the initial priming phase. IL-
2, in contrast, exerts its effect on T cell differentiation at later
times. The integration of all signals finally leads to higher num-
bers of antigen-specific CD8 T cells with enhanced function-
ality and a CD127+ KLRG-1+ phenotype after rMVA-CD40L
immunization.
Remarkably, both, the number and phenotype of B8-specific
CD8 T cells are similar after two immunizations with rMVA
and a single immunization with rMVA-CD40L (Figures 6 and
7 and data not shown). We cannot say whether primary rMVA-
CD40L-induced effector T cells really resemble secondary rMVA-
induced effector T cells in more than the investigated para-
meters. The challenge studies with ECTV at least suggest that,
in contrast to a single rMVA immunization, a high degree of
CTL-mediated protection can be achieved by a single rMVA-
CD40L-immunization, indicative of a more efficacious CTL
response (Figure 11). Whether this is the result of higher num-
bers or enhanced functionality or both remains to be deter-
mined. Furthermore, it would be very interesting to perform
detailed “omical” analyses of the CD8 T cell populations in
rMVA- and rMVA-CD40L-immunized mice in order to reveal the
entire impact rMVA-CD40L-immunization has on the CD8 T cell
response.
The fast generation of high numbers of polyfunctional CTLs
with characteristics of secondary effector cells by rMVA-CD40L
immunization offers clear advantages over non-adjuvanted vec-
tors: (1) lower vaccine doses can be used or fewer vaccinations
performed to reach a similar level of protection; (2) protective
immunity can be established faster – a feature that is important
in emergency settings such as bioterrorism attacks or sudden out-
breaks of disease; (3) protective levels of CTLs might be achievable
with such a vaccine vector even in situations where very high
numbers of polyfunctional CTLs are likely to be required [e.g.,
P. falciparum (14, 15) and HIV/SIV (10, 77)]; (4) the combination
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FIGURE 11 | Improved virus control in B cell deficient mice. (A) In order to
confirm that B cell deficient JHT mice used for challenge studies mount
similar responses as C57BL/6 wt mice, JHT mice were immunized with rMVA
and rMVA-CD40L. Seven days later the frequency of B8-specific CD8 T cells in
the blood was determined by dextramer staining. Note that the percentage of
B8-dextramer CD8 T cells after immunization is comparable between C57BL/6
wt mice and JHT mice (see Figure 6). Data are representative of five mice
per group and two independent experiments. (B) JHT mice were immunized
once with rMVA and rMVA-CD40L or twice with rMVA. Approximately
2 months after the first immunization, mice were infected with 1×105 TCID50
ECTV and monitored daily for disease symptoms and survival. Shown is the
day of disease onset or death. Disease onset was defined as the appearance
of symptoms such as skin lesions, swollen limbs, and tail or, necrotic skin
areas. The data are compiled from three independent experiments. The
numbers depict the number of mice that remained symptom-free of the total
number of mice/group.
of strong innate and adaptive immune responses might allow ther-
apeutic vaccinations against tumors or chronic infections, where
high hurdles such as tolerance or immune inhibitory conditions
must be overcome (78).
Overall, we believe that recombinant MVA vaccines genetically
adjuvanted with CD40L are a major step forward the development
of vaccines against difficult targets that require particular high and
efficient CTL responses for protection.
MATERIALS AND METHODS
ETHICS STATEMENT
All animal experiments were approved by the animal ethics com-
mittee of the government of Upper Bavaria (Regierung von Ober-
bayern, Sachgebiet 54, Tierschutz) and were carried out in accor-
dance with the approved guidelines for animal experiments at
Bavarian Nordic GmbH.
MICE
Mice were bred and maintained either in the animal facilities at
Bavarian Nordic GmbH or at the University of Zurich according
to institutional guidelines. C57BL/6J (H-2b) and CBA/J (H-2k)
mice were purchased from JANVIER LABS. MHC class II defi-
cient (MHC II−/−), CD40 deficient (CD40−/−), CD40L deficient
(CD40L−/−), and JHT mice were on a C57BL/6 background and
were obtained from the animal facility of the University Zurich.
GENERATION OF MVA-BN RECOMBINANTS
All recombinant virus vectors used for this study were based on
a cloned version of MVA-BN® in a bacterial artificial chromo-
some (BAC). MVA-BN® was developed by Bavarian Nordic and is
deposited at the European Collection of Cell Cultures (ECACC)
(V00083008). The generation of MVA recombinants was carried
out as described recently (40). Briefly, the sequence of the strong
synthetic early late pS promoter comprises 40 nucleotides exactly
matching the previously described sequence (41). The pS pro-
moter was cloned upstream of the open reading frame for chicken
OVA. The pHyb promoter was developed and described by Baur et
al. (40) and comprises a late element from the promoter directing
the expression of the ATI protein in cowpox virus (79, 80) and
five tandemly arranged early elements derived from a modified
p7.5 promoter (81). The pHyb promoter was cloned upstream
of the open reading for murine CD40L. Infectious viruses were
reconstituted from BACs by transfecting BAC DNA into BHK-
21 cells and superinfecting them with Shope fibroma virus as a
helper virus. After three additional passages on primary chicken
embryo fibroblasts (CEF), helper virus free MVA-OVA, MVA-
OVA-CD40L, and MVA-ZEBOV-GP viruses were obtained. All
viruses used in animal experiments were purified twice through a
sucrose cushion. For the UV-inactivation of viruses concentrated
virus stocks were UV irradiated with an UV Chamber (Genelinker
GS, Bio-Rad laboratories, Munich Germany) in the presence of
psoralen.
IMMUNIZATION OF MICE
Intravenous injections were given into a lateral tail vein with
a total volume of 200µl containing 5× 107 TCID50 of the
respective MVA recombinants. Where noted, 50µg anti-CD40
Ab (Bio X Cell) were mixed with MVA recombinants or
100µg EndoGrade Ovalbumin (Hyglos) prior to injection.
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For ECTV (strain Moscow) infection, mice were anesthetized
with ketamine/xylazine and virus (1× 105 TCID50) was applied
by intranasal (i.n.) drop wise installation in a total volume
of 50µl. The health status of infected mice was checked
daily.
FLOW CYTOMETRY
Mononuclear cell suspensions were stained with appropriate
dilutions of the following monoclonal antibodies: anti CD3-
FITC, CD3-PECy7, CD4-APC-H7, CD8α-FITC, CD8α-PerCP-
Cy5.5, CD19-FITC, CD19-PerCP-Cy5.5, CD44-FITC, CD62L-
FITC, CD69-FITC, CD80-FITC, CD80-PE, CD86-FITC, NK1.1-
FITC, NK1.1-APC, NK1.1-PerCP-Cy5.5, IL-2-APC, TNF-α-PE
(all BD Biosciences), CD4-Alexa700, CD3-PerCP-Cy5.5, CD8α-
Alexa700, CD8α-eFluor450, CD11b-Alexa700, CD11c-PECy7,
CD25-PE, CD44-PerCP-Cy5.5, CD44-APC-eFluor780, CD45R
(B220)-eFluor780, CD86-eFluor605, CD127-PECy7, CD154
(CD40L)-eFluor780, H-2Kb/SIINFEKL-APC (25-D1.16), KLRG-
1-PerCP-eFluor710, KLRG-1-FITC, IFNγ-PECy7, Bcl-2-FITC (all
eBioscience), and anti-Granzyme B-PE (GRB04, Life Technolo-
gies). APC-conjugated MHC class I H-2Kb dextramers loaded
with B820–27-peptide (TSYKFESV) or PE-conjugated MHC class
I H-2Kb dextramers loaded with OVA257–264-peptide (SIIN-
FEKL) were used according to the manufacturer’s instruc-
tions (Immudex). For intracellular cytokine staining, cells were
incubated with 2.5µg/ml of MHC class I restricted peptides
[B820–27, OVA257–264, or ZEBOV-GP577–584 (TELRTFSI)] for 5–
6 h at 37°C in complete RPMI in the presence of 1µl/ml
GolgiPlug (BD Biosciences). Peptides were purchased from
GenScript. Intracellular staining of IFN-γ, TNF-α, and IL-2
was performed after fixation/permeabilization according to the
manufacturer’s instructions (BD Cytofix/Cytoperm, BD Bio-
sciences). In order to measure cell proliferation 100µg EdU
were injected i.v. into MVA immunized animals. Spleens were
removed 1 h later for surface staining and subsequent EdU
staining according to the manufacturer’s instructions (Click-iT
EdU Alexa Fluor488 Flow cytometry Assay Kit, Life Technolo-
gies). For live/dead discrimination cells were stained before fixa-
tion according to the manufacturer’s instructions (LIVE/DEAD
fixable violet dead cell staining kit, Life Technologies). All
cells were acquired using a digital flow cytometer (LSR II,
BD Biosciences) and data were analyzed with FlowJo software
(Tree Star).
IN VIVO CTL ASSAY
The in vivo CTL assay was essentially performed as described
before (82) but extended to two target cell populations. Briefly,
mononuclear spleen cell suspensions from naïve mice were
incubated at ∼2× 107 cells/ml with 20µg/ml B820–27-peptide,
OVA257–264-peptide, or without peptide for 1 h at 37°C. Each
spleen cell population was labeled with 5µM CFSE (Life Technolo-
gies), 0.5µM CFSE or 5µM eFluor670 (eBioscience) for 10 min
at 37°C. Labeling was stopped by addition of 10 ml FCS. Washed
cells were mixed at a 1:1:1 ratio and 1–2× 107 cells were injected
i.v. into syngeneic naïve and immunized mice. Mice were sacri-
ficed after 4 h and mononuclear spleen cell suspensions prepared.
Cells were analyzed flow cytometrically. PSL of fluorescent tar-
get cells was calculated as follows: ratio= percentage of unpulsed
cells/percentage of pulsed cells; PSL= (1−ratio unprimed/ratio
primed)× 100.
IN VITRO DC STIMULATION
FLT3-L bone marrow culture derived DCs were prepared as
described (83). For in vitro analysis of DC activation and gene
expression, wt FLDCs were transduced with MVA-OVA or MVA-
OVA-CD40L (MOI 2). Three, six, and nine hours later DCs were
harvested and stained for flow cytometric analysis. Supernatant
was kept for cytokine analysis.
CYTOKINE DETECTION
Cytokine concentrations in serum and supernatant of FLDC cul-
tures were determined by FlowCytomix bead assay (eBioscience)
according to the manufacturer’s instructions.
STATISTICAL ANALYSIS
Statistical significance was calculated using an unpaired, two-tailed
Student’s t -test. p-Values of <0.05 were considered statistically
significant (∗) and p-values of <0.005 were considered highly
statistically significant (∗∗).
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